Chrysa Mineo serves as Independent Director of the Company. From 2009 to 2015, Ms. Mineo led corporate development at Receptos, Inc., a biotechnology company acquired by Celgene Corp. in 2015. Prior to Receptos, from 1997 to 2009 Ms. Mineo held roles of increasing business development responsibility at Neurocrine Biosciences, a biotechnology company. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen Inc., DNAX Research Institute, Schering Plough Corporation and Baxter Biotech. Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and an M.B.A. from Duke University’s Fuqua School of Business. In addition, Ms. Mineo is a Trustee at the San Diego French American School, a member of the Director’s Council at the Scripps Institution of Oceanography, and a member of the Board of Directors of the San Diego Natural History Museum.
As the Independent Director of Cidara Therapeutics Inc, the total compensation of Chrysa Mineo at Cidara Therapeutics Inc is $64,447. There are 8 executives at Cidara Therapeutics Inc getting paid more, with Jeffrey Stein having the highest compensation of $1,451,970.
Chrysa Mineo is 55, she's been the Independent Director of Cidara Therapeutics Inc since 2018. There are 7 older and 11 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
Chrysa's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio..., eSteve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: